Gene Therapy for Cardiovascular Diseases

Introduction:

The growing fascination with gene therapy for vascular issues finds its roots in the shortcomings of long-term drug treatments for complex cardiovascular diseases. Specifically tailored for cardiovascular conditions, gene transfer proves instrumental in fostering therapeutic blood vessel growth in oxygen-deprived muscles, regulating high blood pressure, and averting the recurrence of arterial blockages. The article will unravel diverse gene delivery approaches designed to target specific diseases.

What Is Gene Therapy?

Gene therapy involves the modification of a person's genes to address a disease, thereby transforming the biological characteristics of cells. The primary methods encompass:

1. Substituting the defective gene with healthy counterparts.

2. Deactivating the gene responsible for the disease.

3. Incorporating a new gene for therapeutic objectives.

Diverse forms of gene therapy encompass:

1. The plasmid DNA (Deoxyribonucleic Acid) approach involves the genetic engineering of circular DNA molecules carrying therapeutic genes.

2. Viral vector technique, employing modified viruses (rendered non-infectious) known as vectors to transport genetic material into cells.

3. Bacterial vector method, utilizing modified bacteria (vectors) to deliver genetic material into cells.

4. Patient-derived cellular gene therapy products, where cells are extracted, modified, and subsequently reintroduced into the patient.

5. Human gene editing technology disrupts harmful genes or repairs mutated genes.

What Is Gene Therapy for Cardiovascular Diseases?

Gene therapy in the context of cardiovascular diseases involves manipulating, modifying, or controlling genes to treat and prevent various conditions. Specific genes related to conditions like ischemia, vein graft failure, blood clotting or thrombosis, atherosclerosis, and hypertension are specifically addressed on a genetic level as part of the treatment approach.

1. Ischemia: Peripheral ischemic diseases notably impact the lower extremities, resulting from reduced blood supply due to blocked or narrowed arteries. The term myocardial ischemia is used when this condition occurs in the heart. Ongoing clinical studies employ therapeutic genes, focusing on Fibroblast Growth Factor (FGF) and angiogenic growth factors. Within the gene therapy domain, a modified virus (AdVEGF121) carrying the VEGF (vascular endothelial growth factor) gene has demonstrated positive outcomes, showing improved endothelial function and enhanced blood flow in the lower extremities. Additionally, gene therapy is an adjunct intervention for reperfusion injury, where previously deprived heart muscles undergo damage due to oxidative stress. Hypoxic regulatable elements are utilized to mitigate oxidative stress in such scenarios.

2. Late Vein Graft Failure: Despite the common use of Coronary Artery Bypass Grafts (CABG) to enhance the lives of angina patients, their long-term success is often constrained by graft failure, prompting the need for anti-thrombotic medications. Graft failure not only results in vessel narrowing but also highlights the potential of gene therapy in modifying vein grafts. Genes that inhibit matrix metalloproteinases (MMPs) can be crucial in preventing graft failure. Another avenue involves the application of gene therapy to overexpress Tissue Inhibitors of MMPs (TIMPs), effectively impeding new blood vessel formation. Introducing Neuronal Nitric Oxide Synthase (nNOS) gene therapy has exhibited promise in enhancing graft remodeling by increasing nitric oxide (NO) activity and reducing inflammation. However, a comprehensive understanding of their effectiveness necessitates long-term studies.

3. Atherosclerosis: Gene transfer of LDL- or VLDL-receptors emerges as a crucial strategy to counter deficiencies associated with atherosclerosis (gradual formation of fatty deposits within blood vessels). This gene therapy approach directly tackles receptor deficiencies that contribute significantly to atherosclerosis. Additionally, gene therapy focused on reducing apolipoprotein B100 or lipoprotein A provides an extra layer of protection, further lowering the risk of atherosclerosis.

4. Thrombosis: Two main genes associated with antiplatelet and anticoagulant activities are playing a crucial role in preventing blood clotting. Gene therapy offers a promising means to enhance the effectiveness of tPA (Tissue Plasminogen Activator), known for its clot-dissolving capabilities. The positive outcomes of tPA overexpression hold significant benefits, particularly in procedures like peripheral artery angioplasty (a medical procedure designed to treat blocked blood vessels), intravascular stenting (positioning a stent inside a blood vessel), and coronary artery bypass grafting.

5. Hypertension: Dealing with hypertension (elevated blood pressure) is a complex task. The realm of gene therapy, particularly directed at the Renin-Angiotensin System (RAS), is an active area of research for potential solutions. Despite encouraging results in laboratory studies, the practical application of gene therapy for hypertension awaits clear demonstrations in clinical settings.

What Are the Strategies for Gene Delivery?

Several approaches exist for introducing therapeutic genes into blood vessels:

• Ex Vivo Gene Therapy: Specifically selected for addressing challenges like vein graft failure, this approach involves modifying vascular tissues outside the body using a vector. Notably safe, it reduces the risk of unwanted gene expression in other body parts. Additionally, the removal of excess virus minimizes the immune response. As an illustration, in procedures like Coronary Artery Bypass Surgery (CABG), blood vessels can be extracted, modified externally with therapeutic genes, and then re-implanted into the patient.

• Cell-Based Genetic Modification: Similar to the ex vivo gene therapy approach, gene modification occurs outside the body. Cells are sourced from the patient, undergo modification, and reintroduced into the patient. This method exhibits promise in treating familial hypercholesterolemia, aiming to address elevated cholesterol levels. A recent study observed partial success in reducing cholesterol levels through this method.

• Local Gene Delivery in Vivo: When blood vessels pose accessibility challenges, resorting to local delivery methods is essential, and catheters serve as valuable tools. Specially designed catheters, guided by X-ray fluoroscopy, can deliver genes with precision, making the vessel's inner space visible using a contrast medium. Another avenue for localized gene transfer involves the use of stents. A recent study demonstrated stable gene expression in blood vessels through a stent coated with fibronectin and seeded with Green Fluorescent Protein (GFP) transduced smooth muscle cells. Despite these advancements, ongoing research explores various devices for local gene therapy to improve precision.

• Systemic Gene Delivery: The accumulation of viral vectors in the liver poses a delivery challenge for therapeutic genes. Nevertheless, the liver can effectively alter lipid metabolism and be a production site for therapeutic proteins released into the bloodstream. This dual role of the liver presents opportunities for treating conditions such as high cholesterol and hypertension.

Conclusion:

Tackling cardiovascular disorders is a complex endeavor, given their intricate nature. The challenge lies in identifying the most appropriate gene recognizing that a combination of genes is more effective than a solitary one. For gene therapy to transition into a practical solution in cardiovascular clinics, researchers must pinpoint and develop effective therapeutic genes and suitable delivery vectors. The encouraging initial results mark a positive advancement toward realizing the potential of gene therapy for managing cardiovascular conditions.